

ASPIRIN AND DISEASE STATE

BIBLIOGRAPHY



Please see the accompanying Full Prescribing Information.

Table of Contents

<i>I. Low-Dose Aspirin: A Review of Efficacy, Outcomes and Safety.....</i>	<i>3</i>
<i>II. Cardiovascular & Cerebrovascular Disease: Reviews and Secondary Prevention Guidelines</i>	<i>5</i>
<i>III. Secondary Cardiovascular Prevention in Patients with Diabetes</i>	<i>7</i>
<i>IV. Secondary Cardiovascular Prevention in Patients with Established Cardiovascular Disease</i>	<i>9</i>
<i>V. DURLAZA®</i>	<i>12</i>
<i>VI. Adherence to Cardiovascular Medications: A Review of the Issues Related to Medication Adherence and the Pharmacoeconomic Impact of Non-Adherence.....</i>	<i>13</i>

Please see the accompanying Full Prescribing Information.

I. Low-Dose Aspirin: A Review of Efficacy, Outcomes and Safety

- Stolarek W, Kasprzak M, Obonska K, et al. Acetylsalicylic acid resistance risk factors in patients with myocardial infarction. *Pharmacol Rep*. 2015; 67(5):952-958.
- Aksu HU, Oner E, Celik O, et al. Aspirin resistance in patients undergoing hemodialysis and effect of hemodialysis on aspirin resistance. *Clin Appl Thromb Hemost*. 2015; 21(1):82-86.
- Bethel MA, Harrison P, Sourij H, et al. Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes [published online ahead of print June 4, 2015]. *Diabet Med*. 2015.
- Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP. 2015.
- Lin KJ, De CR, Garcia Rodriguez LA. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study. *Circ Cardiovasc Qual Outcomes*. 2014; 7(1):70-77.
- Patrignani P, Tacconelli S, Piazzuelo E, et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. *J Thromb Haemost*. 2014; 12(8):1320-1330.
- Floyd CN. Mechanisms of aspirin resistance. *Pharmacology & Therapeutics* 141 (2014) 69–78.
- Rosiak M, Postula M, Kaplon-Cieslicka A, et al. The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study. *Kardiol Pol*. 2013; 71(6):552-557.
- Grove EL. Antiplatelet effect of aspirin in patients with coronary artery disease. *Dan Med J*. 2012; 59(9):B4506.
- Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. *Blood*. 2012; 119(15):3595-3603.
- Dillinger JG, Drissa A, Sideris G, et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. *Am Heart J*. 2012; 164(4):600-606.
- Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. *Circulation*. 2011; 123(7):768-778.
- Gachet C. Testing Antiplatelet Therapy. *Eur Heart Journal*. 2011;10(suppl):A28-A34.
- Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. *Circ Cardiovasc Interv*. 2011; 4(2):180-187.
- Spectre G, Arnetz L, Östenson CG, Brismar K, Li N, Hjerdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. *Thromb Haemost*. 2011; 106(3):491-499.
- Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. *Cardiovasc Diabetol*. 2011; 1025.
- Bliden KP; Tantry US; DiChiara J; Gurbel PA. EDITORIAL Further Ex Vivo Evidence Supporting Higher Aspirin Dosing in Patients With Coronary Artery Disease and *Diabetes Circ Cardiovasc Interv*. 2011;4:118-120.
- Addad F, Chakroun T, Elalamy I, et al. Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. *Int J Hematol*. 2010; 92(2):296-301.
- Herlitz J. Low-Dose Aspirin Therapy for Cardiovascular Prevention Quantification and Consequences of Poor Compliance or Discontinuation. *Am J Cardiovasc Drugs* 2010; 10 (2): 125-141.
- Tantry US, Mahla E, Gurbel PA. Aspirin resistance. *Prog Cardiovasc Dis*. 2009; 52(2):141-152.

Please see the accompanying Full Prescribing Information.

- Foussas SG, Zairis MN, Tsirimpis VG, et al. The impact of aspirin resistance on the long-term cardiovascular mortality in patients with non-ST segment elevation acute coronary syndromes. *Clin Cardiol.* 2009; 32(3):142-147.
- Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. *BMJ.* 2008; 336(7637):195-198.
- Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. *J Am Coll Cardiol.* 2008; 51(19):1829-1843.
- Bhatt D. et al. ACC/AHA 2008 Consensus on Reducing Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. *Circulation* 2008; 118:1894-1909.
- Duzenli MA, Ozdemir K, Aygul N, Soyulu A, Tokac M. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. *Am J Cardiol.* 2008; 102(4):396-400.
- DiChiara J. The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients: An Analysis from the Aspirin-Induced Platelet Effect (ASPECT) Study. *Diabetes* 56:3014–3019, 2007.
- Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjerdahl P. Dose- and time-dependent antiplatelet effects of aspirin. *Thromb Haemost.* 2006; 95(4):652-658.
- Serebruany VL. Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials. *Am J Cardiol.* 2005; 95:1218–1222.
- Rainsford KD. Aspirin and Related Drugs. New York, NY: Taylor & Francis Inc; 2004.
- Van HA, Juliano ML, Depre M, et al. Effects of enteric-coated, low-dose aspirin on parameters of platelet function. *Aliment Pharmacol Ther.* 2002; 16(9):1683-1688.
- Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. *J Pharm Biomed Anal.* 1999; 21(2):383-392.
- Bode-Boger SM, Boger RH, Schubert M, Frolich JC. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. *Eur J Clin Pharmacol.* 1998; 54(9-10):707-714.
- Muir N, Nichols JD, Clifford JM, Stillings MR, Hoare RC. The influence of dosage form on aspirin kinetics: implications for acute cardiovascular use. *Curr Med Res Opin.* 1997; 13(10):547-553.
- Benedek IH, Joshi AS, Pieniaszek HJ, King SY, Kornhauser DM. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. *J Clin Pharmacol.* 1995; 35(12):1181-1186.
- Bochner F, Somogyi AA, Wilson KM. Bioequivalence of four 100 mg oral aspirin formulations in healthy volunteers. *Clin Pharmacokinet.* 1991; 21(5):394-399.
- Cairns JA, Gent M, Singer J, et al. Aspirin, sulfipyrazone, or both in unstable angina. Results of a Canadian multicenter trial. *N Engl J Med.* 1985; 313(22):1369-1375.
- Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. *N Engl J Med.* 1984; 311(19):1206-1211.
- Lewis HD, Jr., Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. *N Engl J Med.* 1983; 309(7):396-403.
- Patrono C, Ciabattini G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. *Thromb Res.* 1980; 17(3-4):317-327.
- A randomized trial of aspirin and sulfipyrazone in threatened stroke. The Canadian Cooperative Study Group. *N Engl J Med.* 1978; 299(2):53-59.

Please see the accompanying Full Prescribing Information.

II. Cardiovascular & Cerebrovascular Disease: Reviews and Secondary Prevention Guidelines

- Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. *Circulation*. 2015; 131(4):e29-e322.
- Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and American college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. *Endocr Pract*. 2015; 21(0):1-87.
- American Diabetes Association. Standards of Medical Care in Diabetes 2014. *Diab Care*. 2014; 37(Suppl1):S14-S80.
- January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2014.
- Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014; 45(7):2160-2236.
- Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. *N Engl J Med*. 2013; 368(21):2004-2013.
- Patrono C. Chapter 111: Antiplatelet Therapy. In Marder VJ (ed): *Hemostasis and Thrombosis*. Lippincott Williams & Wilkins. 6th Edition. 2013.
- Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J*. 2013; 34(39):3035-3087.
- Schnell O, Erbach M, Hummer M. Primary and Secondary Prevention of Cardiovascular Disease in Diabetes with Aspirin. *Diab and Vasc Dis Res*. 2012; 9:245-255.
- Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. *Arch Intern Med*. 2012; 172(3):209-216.
- Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012; 141(2)(Suppl):e637S-e668S.
- Perk J, De BG, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J*. 2012; 33(13):1635-1701.
- Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. *N Engl J Med*. 2012; 366(21):1959-1967.
- Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012; 141(2 Suppl):e669S-e690S.
- Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. 2012; 126(7):875-910.
- Smith SC, Jr., Benjamin EJ, Bonow RO, et al; The World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for

Please see the accompanying Full Prescribing Information.

Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. *Circulation*. 2011; 124(22):2458-2473.

- Furie KL, Kasner SE, Adams RJ, et al; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2011; 42(1):227-276.
- Lièvre M, Cucherat M. Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis. *Fundam Clin Pharmacol*. 2010; 24(3):385-391.
- Baigent C, Blackwell L, Collins R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*. 2009; 373(9678):1849-1860.
- Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. *Diabet Med*. 2009; 26(2):142-148.
- Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement. U.S. Preventive Services Task Force. *Ann Intern Med*. 2009; 150:396-404.
- Ling G. Oral Antiplatelet Therapy in the Secondary Prevention of Atherothrombotic Events. *Am J Cardiovasc Drugs* 2009; 9 (3): 197-209.
- Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008; 133(6 Suppl):776S-814S.
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005; 352(16):1685-1695.
- Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. *N Engl J Med*. 2005; 353(22):2373-2383.
- Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002; 324(7329):71-86.
- Antithrombotic Trialists' Collaboration (ATC). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002; 324:71–86.
- Steering Committee of the Physicians' Healthy Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. *N Engl J Med*. 1989; 321(3):129-135.

Please see the accompanying Full Prescribing Information.

III. Secondary Cardiovascular Prevention in Patients with Diabetes

- Bell DS. Aspirin in the Prevention of Cardiovascular Events in Patients with Diabetes. *Postgrad Med*. 2016. Jan 12:1-11. [Epub ahead of print].
- Larsen S, Grove E, Neergaard-Petersen S, Würtz M, Hvas A, Kristensen S. Determinants of Reduced Antiplatelet Effect of Aspirin in Patients with Stable Coronary Artery Disease. 2015 PLoS ONE 10(5): e0126767.
- Cavender MA, Steg PG, Smith SC, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PWF, Bhatt DL. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. *Circulation*. 2015;132:923-931.
- Bethel MA, Harrison P, Sourij H, et al. Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes [published online ahead of print June 4, 2015]. *Diabet Med*. 2015.
- Kumbhani DJ, Marso SP, Alvarez CA, McGuire DK. State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus. *Curr Cardiovasc Risk Rep*. 2015; 94.
- Zaccardi F, Rocca B, Pitocco D, Tanese L, Rizzi A, Ghirlanda G. Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis. *Diabetes Metab Res Rev*. 2015; 31(4):402-410.
- Simpson SH, Abdelmoneim AS, Omran D, Featherstone TR. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. *Am J Med*. 2014;127(1):e1-95.e9.
- Kim JD, Park CY, Ahn KJ, et al. Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes. *Atherosclerosis*. 2014; 234(1):146-151.
- Labuz-Roszak B, Pierzchala K, Tyrpien K. Resistance to acetylsalicylic acid in patients with type 2 diabetes mellitus is associated with lipid disorders and history of current smoking. *J Endocrinol Invest*. 2014; 37(4):331-338.
- Tasdemir E, Toptas T, Demir C, Esen R, Atmaca M. Aspirin resistance in patients with type II diabetes mellitus. *Ups J Med Sci*. 2014; 119(1):25-31.
- Rosiak M, Postula M, Kaplon-Cieslicka A, et al. The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study. *Kardiol Pol*. 2013; 71(6):552-557.
- Schnell O, Erbach M, Hummer M. Primary and Secondary Prevention of Cardiovascular Disease in Diabetes with Aspirin. *Diab and Vasc Disease Research*. 2012; 9:245-255.
- Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. *Circ Cardiovasc Interv*. 2011; 4(2):180-187.
- Spectre G, Arnetz L, Östenson CG, Brismar K, Li N, Hjerdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. *Thromb Haemost*. 2011; 106(3):491-499.
- Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. *Cardiovasc Diabetol*. 2011; 1025.
- Bliden KP; Tantry US; DiChiara J; Gurbel PA. EDITORIAL Further Ex Vivo Evidence Supporting Higher Aspirin Dosing in Patients with Coronary Artery Disease and Diabetes. *Circ Cardiovasc Interv*. 2011; 4:118-120.

Please see the accompanying Full Prescribing Information.

- Ferreiro J, Gómez-Hospital J, Angiolillo D. Platelet abnormalities in diabetes mellitus. *Diabetes & Vascular Disease Research*. 2010; 7(4):251-259.
- Addad F, Chakroun T, Elalamy I, et al. Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. *Int J Hematol*. 2010; 92(2):296-301.
- Bulughapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. *Diabet Med*. 2009; 26(2):142-148.
- Duzenli MA, Ozdemir K, Aygul N, Soylu A, Tokac M. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. *Am J Cardiol*. 2008; 102(4):396-400.
- Cohen HW, Crandall JP, Hailpern SM, Billett HH. Aspirin resistance associated with HbA1c and obesity in diabetic patients. *J Diabetes Complications*. 2008; 22(3):224-228.
- Hovens M, Snoep J, Eikenboom J, van der Bom J, Mertens B, Huisman M. Prevalence of persistent platelet reactivity despite use of aspirin - A systematic Review. *Am Heart J*. 2007; 153:175281.
- DiChiara J. The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients: An Analysis from the Aspirin-Induced Platelet Effect (ASPECT) Study. *Diabetes* 56:3014–3019, 2007.
- Cabeza N, Li Z, Schulz C, et al. Surface expression of collagen receptor Fc receptor-gamma/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells. *Diabetes*. 2004; 53(8):2117-2121.
- Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. *Diabetes Care*. 2003; 26(7):2181-2188.

Please see the accompanying Full Prescribing Information.

IV. Secondary Cardiovascular Prevention in Patients with Established Cardiovascular Disease

- Dretzke J, Riley RD, Lordkipanidze M, et al. The prognostic utility of tests of platelet function for the detection of 'aspirin resistance' in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. *Health Technol Assess*. 2015; 19(37):1-366.
- Montalescot G, Range G, Silvain J, et al. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study. *Circulation*. 2014; 129(21):2136-2143.
- Gouya G, Arrich J, Wolzt M, et al. Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. *Stroke*. 2014; 45(2):492-503.
- Gasparovic H, Petricevic M, Kopjar T, Djuric Z, Svetina L, Biocina B. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. *Am J Cardiol*. 2014; 113(10):1660-1667.
- Grimaldi R, Bisi M, Lonni E, et al. Laboratory aspirin resistance reversibility in diabetic patients: a pilot study using different pharmaceutical formulations. *Cardiovasc Drugs Ther*. 2014; 28(4):323-329.
- Li J, Song M, Jian Z, et al. Laboratory aspirin resistance and the risk of major adverse cardiovascular events in patients with coronary heart disease on confirmed aspirin adherence. *J Atheroscler Thromb*. 2014; 21(3):239-247.
- Meves SH, Hummel T, Endres HG, et al. Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD. *J Thromb Thrombolysis*. 2014; 37(2):190-201.
- Karolczak K, Pietruszynski R, Drzewoski J, Kasznicki J, Watala C. Aspirin dose increase from 75 to 150 mg suppresses red blood cell contribution to suboptimal platelet response to aspirin in patients with CAD. *Cardiovasc Drugs Ther*. 2013; 27(6):549-558.
- Wong KS, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. *Circulation*. 2013; 128(15):1656-1666.
- Fitzgerald DF, FitzGerald G. Cyclooxygenase Inhibition and P2Y12 Antagonism. *Circ Res*. 2013; 112:174-194.)
- Maron BA. Chapter 40: Nitric Oxide: The Vascular Biology of Nitric Oxide and Nitric Oxide Synthases. In Marder VJ (ed): *Hemostasis and Thrombosis*. Lippincott Williams & Wilkins. 6th Edition. 2013.
- Bark D. Chapter 29: Shear Effects on Platelets and the vessel Wall in the Pathogenesis of Atherothrombosis. In Marder VJ (ed): *Hemostasis and Thrombosis*. Lippincott Williams & Wilkins. 6th Edition. 2013.
- Pettersen AA, Arnesen H, Opstad TB, Bratseth V, Seljeflot I. Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease. *Thromb Res*. 2012; 130(3):424-428.
- Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. *Eur Heart J*. 2012; 33(24):3078-3087.
- Geeganage CM, Diener HC, Algra A, et al. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. *Stroke*. 2012; 43(4):1058-1066.
- Salama MM, Morad AR, Saleh MA, Sabri NA, Zaki MM, ElSafady LA. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors. *J Clin Pharm Ther*. 2012; 37(6):630-636.

Please see the accompanying Full Prescribing Information.

- Smith JP, Haddad EV, Taylor MB, et al. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. *Hypertension*. 2012; 59(3):719-725.
- Mendes RT, Stanczyk CP, Sordi R, Otuki MF, dos Santos FA, Fernandes D. Selective inhibition of cyclooxygenase-2: risks and benefits. *Rev Bras Reumatol*. 2012; 52(5):767-782.
- Santilli N. Platelet activation in obesity and metabolic syndrome. *Obesity Reviews* (2012) 13, 27–42.
- Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. *J Thromb Haemost* 2011; 9: 185–91.
- Lordkipanidze M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. *Int J Cardiol*. 2011; 150(1):39-44.
- Park JG, Oh GT. The role of peroxidases in the pathogenesis of atherosclerosis. *BMB Rep*. 2011; 44(8):497-505.
- Lordkipanidze M, Diodati JG, Turgeon J, Schampaert E, Palisaitis DA, Pharand C. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. *Int J Cardiol*. 2010; 143(1):43-50.
- Remkova A, Remko M. The role of renin-angiotensin system in prothrombotic state in essential hypertension. *Physiol Res*. 2010; 59(1):13-23.
- Muir AR, McMullin MF, Patterson C, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. *Heart*. 2009; 95(15):1225-1229.
- Vaidya D, Yanek LR, Faraday N, Moy TF, Becker LC, Becker DM. Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. *Metab Syndr Relat Disord*. 2009; 7(4):289-296.
- Vaduganathan M, Alviar CL, Arikan ME, et al. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. *Am Heart J*. 2008; 156(5):1002.
- Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. *Eur Heart J*. 2007; 28(14):1702-1708.
- Guthikonda S, Lev EI, Patel R, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. *J Thromb Haemost*. 2007; 5(3):490-496.
- Wang TH, Bhatt DL, Fox KA, et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. *Eur Heart J*. 2007; 28(18):2200-2207.
- Davi G, Patrono C. Platelet activation and atherothrombosis. *N Engl J Med*. 2007; 357(24):2482-2494.
- Taubert D. Aspirin induced nitric oxide release from vascular endothelium. *Br J Pharmacol* 2004; 143:159-165.
- Malhotra S, Sharma YP, Grover A, et al. Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease. *Intern Med J*. 2003; 33(8):350-354.
- Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. *Proc Natl Acad Sci U S A*. 2002; 99(11):7634-7639.
- Minuz P, Patrignani P, Gaino S, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. *Circulation*. 2002; 106(22):2800-2805.
- Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. *Proc Natl Acad Sci USA*. 1993; 90(24):11693-11697.
- Handin RI. Chapter 58: Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease. In Braunwald E (ed): *Heart Disease. A Textbook of Cardiovascular Medicine*. WB Saunders. 4th Edition. 1992. pp1767-1789.

Please see the accompanying Full Prescribing Information.

- Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. *N Engl J Med.* 1991; 325(16):1137-1141.
- Patrano C. Clinical pharmacology of platelet cyclooxygenase inhibition. *Circulation* 72, No. 6, 1177-1184, 1985.
- FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. *J Clin Invest.* 1983; 71(3):676-688.

Please see the accompanying Full Prescribing Information.

V. DURLAZA[®]

- Bell DS. Aspirin in the Prevention of Cardiovascular Events in Patients with Diabetes. *Postgrad Med.* 2016. Jan 12:1-11. [Epub ahead of print].
- Bliden KP, Patrick J, Pennell AT, Tantry US, Gurbel PA. Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. *Future Cardiol.* 2016.
- Patrick J, Dillaha L, Armas D, Sessa W. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. *Postgrad Med.* 2015; 127(6):573-580.
- Lassiter M, Mount J. DURLAZA[™] (aspirin): Extended-Release Aspirin for Prevention of Recurrent Cardiovascular Events. *Pharmacy Times.* October 2015.
- Gurbel PA, Bliden KP, Patrick J, Saadin K, Tantry U. Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic acid, DURLAZA in Patient with Diabetes. *Circulation.* 2015; 132: A19503.
- Durlaza (aspirin) extended-release capsules for oral use prescribing information. New Haven Pharmaceuticals, Inc; New Haven, CT: Sept. 2015

Please see the accompanying Full Prescribing Information.

VI. Adherence to Cardiovascular Medications: A Review of the Issues Related to Medication Adherence and the Pharmacoeconomic Impact of Non-Adherence

- Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. *Am J Med.* 2013; 126(4):357.
- Naderi SH. Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients. *American Journal of Medicine* (2012) 125, 882-887.
- Bushnell CD. Secondary preventive medication persistence and adherence 1 year after stroke. *Neurology.* 2011;77:1182–1190.
- Cuisseta T. Non-adherence to aspirin in patients undergoing coronary stenting: Negative impact of comorbid conditions and implications for clinical management. *Archives of Cardiovascular Disease* (2011) 104, 306—312.
- Straka RJ, Liu LZ, Prafulla SG, et al. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. *Cardiovascular Diabetology.* 2009; 8:53.
- Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. *Circulation.* 2006; 113(2):203-212.
- Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. *Eur Heart J.* 2006; 27(22):2667-2674.
- Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study. *Arch Intern Med.* 1994; 154(23):2649-2657.

Please see the accompanying Full Prescribing Information.

Notes:



© 2016 New Haven Pharmaceuticals, Inc.
116 Washington Avenue, 4th Floor, North Haven, CT 06473
DUR_DAP019_160131
February 17, 2016

All trademarks are the property of their respective owners. DURLAZA[®] is a registered trademark of New Haven Pharmaceuticals, Inc. and is registered with the USPTO.

Please see the accompanying Full Prescribing Information.